C4 Therapeutics
CCCC
75 hedge funds and large institutions have $744M invested in C4 Therapeutics in 2020 Q4 according to their latest regulatory filings, with 75 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
52.77% more ownership
Funds ownership: 0% → 52.77% (+53%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
+$91.6M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$72.2M |
| 3 |
RI
RTW Investments
New York
|
+$62.3M |
| 4 |
BCLSI
Bain Capital Life Sciences Investors
Boston,
Massachusetts
|
+$47.6M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$44.4M |
Top Sellers
CCCC Hedge Fund Activity: Q4 2020 in Review
75 of the 5,676 institutional investors tracked by Wall St. Rank reported a position in C4 Therapeutics (CCCC) for Q4 2020, worth a combined $744M.
Buyers outnumbered sellers: 75 funds opened new CCCC positions and 0 closed out — a net gain of 75 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Perceptive Advisors, opening a new position worth an estimated $91.6M.
- 75 institutional investors held C4 Therapeutics (CCCC) as of Q4 2020, up from 0 in Q3 2020.
- Funds reported $744M of C4 Therapeutics stock for Q4 2020.
- 75 funds opened new C4 Therapeutics positions in Q4 2020 and 0 closed out, a net change of +75 holders.
- The largest C4 Therapeutics buyer in Q4 2020 was Perceptive Advisors, an estimated $91.6M added.
Based on aggregated 13F filings for Q4 2020.